US 8889627
Treatment of multiple sclerosis with combination of laquinimod and fingolimod
granted A61KA61K31/137A61K31/47
Quick answer
US patent 8889627 (Treatment of multiple sclerosis with combination of laquinimod and fingolimod) held by TEVA PHARMACEUTICAL INDUSTRIES, LTD. expires Mon Nov 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- TEVA PHARMACEUTICAL INDUSTRIES, LTD.
- Grant date
- Tue Nov 18 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 20
- CPC classes
- A61K, A61K31/137, A61K31/47, A61K31/4704, A61K45/06